Spyre Therapeutics Inc. (SYRE) Statistics & Valuation Metrics - Stocknear

Spyre Therapeutics Inc.

NASDAQ: SYRE · Real-Time Price · USD
17.00
0.01 (0.06%)
At close: Sep 05, 2025, 3:59 PM
17.00
0.00%
After-hours: Sep 05, 2025, 04:10 PM EDT

Spyre Therapeutics Statistics

Share Statistics

Spyre Therapeutics has 60.4M shares outstanding. The number of shares has increased by 18.53% in one year.

60.4M
18.53%
0.16%
16.79%
51.12M
4,330
0.78%

Short Selling Information

The latest short interest is 13.19M, so 21.83% of the outstanding shares have been sold short.

13.19M
21.83%
28.03%
30.5

Valuation Ratios

The PE ratio is -5.26 and the forward PE ratio is -5.14. Spyre Therapeutics's PEG ratio is 0.05.

-5.26
-5.14
0
10424.3
2.11
-6.96
0.05
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Spyre Therapeutics.

n/a
n/a
n/a
n/a

Financial Position

The company has a current ratio of 11.26, with a Debt / Equity ratio of 0.

11.26
11.26
0
n/a
n/a
0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

n/a
n/a
n/a
n/a
$-2.85M
73
0
n/a

Taxes

51K
-0.02%

Stock Price Statistics

The stock price has increased by -39.41% in the last 52 weeks. The beta is 2.83, so Spyre Therapeutics's price volatility has been higher than the market average.

2.83
-39.41%
16.38
18.78
53.52
554,335

Income Statement

n/a
n/a
-208.57M
-208.02M
-207.97M
-207.97M
-0.56
Full Income Statement

Balance Sheet

The company has 89.42M in cash and 0 in debt, giving a net cash position of 89.42M.

89.42M
n/a
n/a
-972.43M
538.83M
455.77M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -157.41M and capital expenditures 0, giving a free cash flow of -157.41M.

-157.41M
n/a
-157.41M
-3.35
Full Cash Flow Statement

Margins

n/a
n/a
n/a
n/a
n/a
n/a
n/a

Dividends & Yields

SYRE does not appear to pay any dividends at this time.

n/a
n/a
n/a
n/a
n/a
n/a
Dividend Details

Analyst Forecast

The average price target for SYRE is $65, which is 282.6% higher than the current price. The consensus rating is "Buy".

$65
282.6%
Buy
4
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

n/a
n/a
n/a
n/a

Stock Splits

The last stock split was on Sep 8, 2023. It was a backward split with a ratio of 1:25.

Sep 8, 2023
backward
1:25

Scores

4.31
1